Warning: The NCBI web site requires JavaScript to function. more...
Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death.
Friedrich JO, Adhikari NK, Meade MO.
Crit Care. 2006;10(6):427. No abstract available.
Related citations
Drotrecogin alfa (activated) in severe sepsis.
Friedrich JO.
N Engl J Med. 2006 Jan 5;354(1):94-6; author reply 94-6. No abstract available.
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR; PROWESS Investigators.
Crit Care Med. 2003 Jan;31(1):12-9.
Baillie JK, Murray G.
Drotrecogin alfa (activated) administration: too many subgroups.
Carlet J.
Crit Care Med. 2003 Oct;31(10):2564; author reply 2564-5. No abstract available.
LaRosa SP.
Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
Barie PS, Hydo LJ, Shou J, Eachempati SR.
Surg Infect (Larchmt). 2006;7 Suppl 2:S77-80. Review.
Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
Ridley S, Lwin A, Wyncoll D, Lippett S, Watson D, Gunning K, Higgins D.
Eur J Anaesthesiol. 2008 Mar;25(3):211-6. Epub 2007 Nov 22.
Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death.
Williams MD, Janes JM, Nelson DR.
Crit Care. 2006;10(5):424. No abstract available.
Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
De Backer D.
Drug Saf. 2007;30(11):995-1010. Review.
Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated).
Rudis MI, Fish DN.
Pharmacotherapy. 2002 Dec;22(12 Pt 2):182S-195S. Review.
Use of drotrecogin alfa (activated) in older patients with severe sepsis.
Alexander SL, Ernst FR.
Pharmacotherapy. 2006 Apr;26(4):533-8. Review.
Criteria for use of drotrecogin alfa.
Jacobi J.
Am J Health Syst Pharm. 2004 Jan 15;61(2):203-4; author reply 204-5. No abstract available.
ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation.
Laterre PF, Abraham E, Janes JM, Trzaskoma BL, Correll NL, Booth FV.
Crit Care Med. 2007 Jun;35(6):1457-63.
Drotrecogin alfa (activated) approved for treatment of severe sepsis.
Poe K.
J Am Pharm Assoc (Wash). 2002 May-Jun;42(3):520-2.
Treating severe sepsis with drotrecogin alfa (activated).
Wyncoll D.
Hosp Med. 2003 Mar;64(3):168-72. Review.
Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.
McCoy C.
Expert Opin Drug Saf. 2004 Nov;3(6):625-37. Review.
Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis.
Pastores SM.
Postgrad Med J. 2003 Jan;79(927):5-10. Review.
Drotrecogin alfa (activated) treatment in severe sepsis: a "journal club" review of the global ENHANCE trial.
Farmer JC.
Crit Care Med. 2005 Oct;33(10):2428-31. No abstract available.
[Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
Bartelink AK.
Ned Tijdschr Geneeskd. 2006 Feb 18;150(7):352-4. Dutch.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on